Korean firm to test new hepatitis B drug

[Guest guest]

Korean firm to test new hepatitis B drug

Date: March 25, 2008

Anti-hepatitis B drugA local pharmaceutical company said Tuesday (Mar. 25) it

will begin clinical tests on an anti-hepatitis B drug that can help liver

disease patients around the world.

Green Cross Co. said the Korea Food and Drug Administration (KFDA) gave its

approval for initial human testing of Hepabig-Gene after reviewing extensive

experiments on laboratory animals that showed the potency and safety of the

drug.

The initial testing is crucial because it can show the effect of the drug and

gauge possible side effects that can halt further development.

Green Cross said it planned to use Hepabig-Gene on patients that received liver

transplants and those suffering from chronic hepatitis B.

The company said animal tests using chimpanzees and monkeys showed the

genetically reconstituted drug kills 3,000 times more liver bacteria than

existing products and is seven times less likely to trigger side effects.

It added that depending of results of the tests on humans, the company is aiming

to further develop the drug to cure hepatitis B.

There are currently no drugs on the market that can cure the disease.

http://www.kois.go.kr/News/News/NewsView.asp?serial_no=20080325012

_________________________________________________________________

How well do you know your celebrity gossip?

http://originals.msn.com/thebigdebate?ocid=T002MSN03N0707A

[Guest guest]

Korean firm to test new hepatitis B drug

Date: March 25, 2008

Anti-hepatitis B drugA local pharmaceutical company said Tuesday (Mar. 25) it

will begin clinical tests on an anti-hepatitis B drug that can help liver

disease patients around the world.

Green Cross Co. said the Korea Food and Drug Administration (KFDA) gave its

approval for initial human testing of Hepabig-Gene after reviewing extensive

experiments on laboratory animals that showed the potency and safety of the

drug.

The initial testing is crucial because it can show the effect of the drug and

gauge possible side effects that can halt further development.

Green Cross said it planned to use Hepabig-Gene on patients that received liver

transplants and those suffering from chronic hepatitis B.

The company said animal tests using chimpanzees and monkeys showed the

genetically reconstituted drug kills 3,000 times more liver bacteria than

existing products and is seven times less likely to trigger side effects.

It added that depending of results of the tests on humans, the company is aiming

to further develop the drug to cure hepatitis B.

There are currently no drugs on the market that can cure the disease.

http://www.kois.go.kr/News/News/NewsView.asp?serial_no=20080325012

_________________________________________________________________

How well do you know your celebrity gossip?

http://originals.msn.com/thebigdebate?ocid=T002MSN03N0707A